| Condensed Balance Sheet [Table Text Block] |
The Company is evaluating the proper accounting treatment for the classification of the Series E Warrants and the allocation of proceeds between common stock, the Series C Preferred Stock, and Additional paid-in capital. All proceeds are included in common stock and additional paid in capital on a pro forma basis .
CELLECTAR BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CURRENT ASSETS: |
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
$ |
4,180,744 |
|
|
$ |
19,068,667 |
|
| Restricted cash |
|
|
55,000 |
|
|
|
55,000 |
|
| Prepaid expenses and other current assets |
|
|
780,559 |
|
|
|
780,559 |
|
| Total current assets |
|
|
5,016,303 |
|
|
|
19,904,226 |
|
| FIXED ASSETS, NET |
|
|
211,970 |
|
|
|
211,970 |
|
| GOODWILL |
|
|
1,675,462 |
|
|
|
1,675,462 |
|
| OTHER ASSETS |
|
|
93,086 |
|
|
|
93,086 |
|
| TOTAL ASSETS |
|
$ |
6,996,821 |
|
|
$ |
21,884,744 |
|
| |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
| CURRENT LIABILITIES: |
|
|
|
|
|
|
|
|
| Accounts payable and accrued liabilities |
|
|
2,093,646 |
|
|
|
2,093,646 |
|
| Derivative liability |
|
|
152,000 |
|
|
|
152,000 |
|
| Capital lease obligations, current portion |
|
|
3,203 |
|
|
|
3,203 |
|
| Deferred rent |
|
|
40,438 |
|
|
|
40,438 |
|
| Total current liabilities |
|
|
2,289,287 |
|
|
|
2,289,287 |
|
| LONG-TERM LIABILITIES: |
|
|
|
|
|
|
|
|
| Capital lease obligation, less current portion |
|
|
568 |
|
|
|
568 |
|
| Total long-term liabilities |
|
|
568 |
|
|
|
568 |
|
| TOTAL LIABILITIES |
|
|
2,289,855 |
|
|
|
2,289,855 |
|
| COMMITMENTS AND CONTINGENCIES (Note 8) |
|
|
|
|
|
|
|
|
| STOCKHOLDERS’ EQUITY: |
|
|
|
|
|
|
|
|
| Preferred stock, $0.00001 par value; 7,000 shares Series C authorized; none actual; 1,114 pro forma |
|
|
— |
|
|
|
— |
|
| Common stock, $0.00001 par value; 80,000,000 shares authorized; 1,774,992 actual; 3,129,992 pro forma |
|
|
17 |
|
|
|
31 |
|
| Additional paid-in capital |
|
|
95,452,779 |
|
|
|
110,340,688 |
|
| Accumulated deficit |
|
|
(90,745,830 |
) |
|
|
(90,745,830 |
) |
| Total stockholders’ equity |
|
|
4,706,966 |
|
|
|
19,594,889 |
|
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
6,996,821 |
|
|
$ |
21,884,744 |
|
|